Related Experiment Videos
Soluble recombinant neutral endopeptidase (CD10) as a potential antiinflammatory agent
N J Solan1, P E Ward, S P Sanders
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA.
Inflammation
|March 4, 1998
Summary
Endogenous neutral endopeptidase-24.11 (NEP-24.11) in joints doesn't regulate inflammatory peptides effectively. However, recombinant NEP-24.11 shows promise for treating inflammatory arthritis.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Endogenous peptides like bradykinin cause joint inflammation.
- Peptide levels are regulated by degrading enzymes, including neutral endopeptidase-24.11 (NEP-24.11).
- NEP-24.11 is abundant on human synovial cells, suggesting a role in local peptide regulation.
Purpose of the Study:
- To investigate the role of endogenous NEP-24.11 in bradykinin-mediated joint inflammation.
- To assess if soluble, recombinant human NEP-24.11 can enhance the effects of the endogenous enzyme.
- To evaluate the stability and activity of recombinant NEP-24.11 in inflammatory conditions.
Main Methods:
- Articular model studies.
- Analysis of endogenous NEP-24.11 activity.
- Administration of soluble recombinant human NEP-24.11.
- Assessment of enzyme activity in the presence of oxidants and inflammatory joint fluids.
Main Results:
- Endogenous synovial NEP-24.11 showed limited modulation of inflammatory peptide effects due to competition with high-density peptide receptors.
- Excess soluble recombinant NEP-24.11 effectively overcame the limitations of the endogenous enzyme.
- Recombinant NEP-24.11 maintained its activity despite the presence of oxidants and inflammatory joint fluids.
Conclusions:
- Endogenous NEP-24.11 activity is insufficient to control inflammatory peptide effects in the joint.
- Recombinant NEP-24.11 is a stable and active enzyme, suggesting therapeutic potential.
- Recombinant NEP-24.11 represents a promising novel therapeutic strategy for inflammatory arthritis.